Abstract 154P
Background
The Australian Pancreatic Screening study offers endoscopic ultrasound surveillance for individuals at increased risk of developing pancreatic cancer. Given 5-10% of pancreatic cancers are linked to genetic predisposition, all participants are required to undergo genetic counselling. We report on the genetic characteristics of this initial cohort from our institution.
Methods
This is a multicentre, prospective cohort study. Individuals with 2 or more family members with pancreatic cancer (including one of first-degree association) and/or those with a known genetic syndrome were defined as high-risk and eligible for study entry. Subjects aged between 40 and 80 years (or 10 years younger than the relative with pancreatic cancer) were included. The study was approved by the Austin Health Human Research Ethics Committee and the first participant consented in July 2013. Data was collected through participant completed questionnaires and review of medical records. All participants were seen by a Familial Cancer Clinic. Those with an indication for further genetic testing were offered gene panel tests. Indications that there may be an inherited predisposition to pancreatic cancer includes; a family history of breast and ovarian cancer, bowel cancer, melanoma, and chronic pancreatitis.
Results
121 participants were recruited from 96 families. In 12 out of 96 families there was a previously known high-risk germline mutation (6 BRCA2, 3 CDKN2A, 2 PALB2 and 1 STK11). 12 out of 84 families with no known mutation were offered genetic testing, either clinic or self-funded and 8 proceeded. Germline pathogenic mutations (Class 4 or 5) were detected in 3/8 families (37.5%), making the overall pick-up rate 3/84 (3.6%). Two families had a BRCA2 mutation and the other a CDKN2A mutation. In one family, where a pathogenic BRCA2 gene mutation was identified, cascade testing identified a further 3 relatives who carried the BRCA2 mutation. The CDKN2A carrier had a significant personal and family history of cutaneous melanoma. 1 participant had a PALB2 variant of uncertain significance.
Conclusions
In an enriched population, based on pedigree and increased genetic susceptibility, the rate of germ line mutations was high. Gene panels should be considered in selected patients undergoing high risk screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Health and Medical Research Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract